Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 217

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 217
---
, 2014, we completed our initial public offering of our Ordinary Shares in the United Kingdom.

On March 31, 2020 we announced
that, in the context of prevailing conditions in the capital markets, we did not expect to be able to raise capital to fund the continued
development of MTD201, including scale-up of MTD201 manufacturing at our Bilbao facilities. We determined to conduct a strategic review
of our operations, cease further investment in MTD201 and close our operations in Bilbao, Spain, including making all our employees in
Bilbao redundant.

On April 20, 2020, we announced
an update to the strategic review of operations including the appointment of Noble Capital Markets, Inc. to advise us on options for extracting
value from our technologies, including partnering our clinical stage assets, partnering existing and upcoming proof of concept formulations,
partnering or selling one or more of our technologies or selling the entire Company.

On January 26, 2021, we announced,
among other things, that the strategic review had completed and that we were now focused on executing our realigned strategy of deploying
our technologies to develop more early stage products and seeking licensing partners at proof of concept stage.

On
March 24, 2023, we held a general meeting where our shareholders approved, among other things, a change of our name to “Biodexa
Pharmaceuticals PLC” and the cancellation of admission of our Ordinary Shares from trading on AIM with effect from April 26, 2023.
Additionally, the names of Midatech Ltd and Midatech Pharma (Wales) Limited were subsequently changed to Biodexa Ltd and Biodexa Pharmaceuticals
(Wales) Limited, respectively.

Our principal executive office
and registered offices are located at 1 Caspian Point, Caspian Way Cardiff, United Kingdom CF10 4DQ, and our telephone number is +44 29
2048 0180. Our authorized representative in the United States is Donald J. Puglisi of Puglisi and Associates. Our agent for service in
the United States is Donald J. Puglisi of Puglisi and Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711. Our
Depositary Shares are traded on the NASDAQ Capital Market under the symbol “BDRX.”

We file reports and other
information with the SEC. The SEC maintains an Internet website that